Review anchor
Macrophage migration inhibitory factor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Macrophage migration inhibitory factor
CHEMBL2085
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Macrophage migration inhibitory factor as ChEMBL target CHEMBL2085, mapped to UniProt P14174. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2085
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P14174
Macrophage migration inhibitory factor
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Macrophage migration inhibitory factor matters
Macrophage migration inhibitory factor is reviewed as Macrophage migration inhibitory factor (UniProt P14174); Macrophage migration inhibitory factor shows late clinical disease relevance led by graft versus host disease. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 593 compounds, and 177 assays, with lead potency reaching pChEMBL 8.7.
Protein context
Macrophage migration inhibitory factor
Macrophage migration inhibitory factor Sequence length is 115 aa.
Review this target as Macrophage migration inhibitory factor, mapped to UniProt P14174. Sequence length is 115 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P14174
Protein
Disease context
graft versus host disease
Macrophage migration inhibitory factor shows late clinical disease relevance led by graft versus host disease. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include IGURATIMOD.
Start review with graft versus host disease because it currently carries late clinical support. Linked drugs include IGURATIMOD. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Late clinical
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 8 approved drugs, 593 compounds, and 177 assays for this target. The dominant activity type is IC50. CHEMBL3752910 is the current potency anchor at pChEMBL 8.7.
Use CHEMBL3752910 as the tractability anchor when discussing potency (pChEMBL 8.7).
Activity source · ChEMBL 36 via Core Engine
8 approved
pChEMBL 8.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Macrophage migration inhibitory factor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P14174, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why graft versus host disease is currently treated as late clinical support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
593
Total Compounds
177
Total Assays
8
Approved Drugs
IC50: 518.0, KI: 221.0, KD: 39.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3752910
|
8.7 | Kd | — |
|
|
No preferred name
CHEMBL1256233
|
8.1 | IC50 | — |
|
|
No preferred name
CHEMBL1255975
|
8.0 | IC50 | — |
|
|
No preferred name
CHEMBL3917143
|
7.8 | Ki | — |
|
|
No preferred name
CHEMBL4779696
|
7.8 | Kd | — |
Source Header